Lunit

Lunit Receivables

The Accounts Receivable of Lunit (328130.KQ) as of Oct 16, 2026 is 1.60 B KRW. In the previous year, Accounts Receivable was 1.35 B KRW — a change of 19.02% (higher).

Receivables

1.60 BKRW

YoY

19.02%

Last updated:

Accounts Receivable of Lunit is 2024 1.60 B KRW. Accounts Receivable of Lunit was 2023 1.35 B KRW. It decreases by 19.02% higher compared to the previous year.

The Lunit Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2019
30.18 M KRW
Jan 1, 2020
354.10 M KRW
Jan 1, 2021
1.32 B KRW
Jan 1, 2022
913.72 M KRW
Jan 1, 2023
1.35 B KRW
Jan 1, 2024
1.60 B KRW
The Lunit Receivables history
YEARReceivablesYoY
1.60 BKRW+19.02%
1.35 BKRW+47.23%
913.72 MKRW-30.82%
1.32 BKRW+273.03%
354.10 MKRW+1,073.47%
30.18 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lunit Stock analysis

What does Lunit do? Lunit Inc is a South Korean company headquartered in Seoul, operating within the Health Care sector. The company has 293 employees and went public on July 21, 2022, with its ticker listed as 328130.KQ and ISIN KR7328130000. Lunit provides software solutions for medical diagnostic imaging services, focusing on the development and supply of AI-powered medical software. Its offerings include cancer diagnostic aid solutions, cancer early detection solutions, and cancer risk prediction solutions. The company's technology leverages artificial intelligence to enhance diagnostic capabilities in healthcare settings. Lunit's website is www.lunit.io, where further information about its services and solutions can be accessed. The company operates in the Health Care industry, specifically targeting medical imaging and AI-driven diagnostic tools. As of the latest available data, Lunit is engaged in the development and commercialization of AI-based medical software, aiming to improve the accuracy and efficiency of cancer-related diagnostics. The firm's IPO date marks its transition to a publicly traded company, reflecting its growth and market position in the healthcare technology space. Lunit's focus on AI applications in medical imaging positions it as a key player in the digital health sector, particularly within the Korean market and beyond. The company's solutions are designed to support healthcare professionals in making more informed diagnostic decisions, potentially reducing the time and resources required for cancer detection and treatment planning. Lunit is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lunit stock

Accounts Receivable of Lunit is 1.60 B KRW in 2024.

Accounts Receivable of Lunit changed from 1.35 B KRW to 1.60 B KRW, representing a 19.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Lunit since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Lunit historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Lunit

All Key Metrics — Lunit